Innovent Biopharmaceutical Transformation
Commercial: Strengthening Our Leadership Position with Strong
Revenue Performance and Expanding Commercial Portfolio
Annual Product Revenue (RMB)
YoY Growth (%)
1.0 bn
+133.0%
TYVYTⓇ
2019
2.4 bn
4.0 bn
Others
+69.0%
2021 achieved +69.0% yoy
growth with synergized portfolio
Tyvyt as leading brand in the market, maintained
satisfactory growth in both revenue and volume.
Higher revenue contribution obtained from other new
launched products with fast ramp-up, which further validates
our commercial platform and capability.
Late stage pipelines covering core disease areas provide near
to mid term sustainable meaningful growth.
2020
SULINNOⓇ
HALPRYZA®
BYVASDAⓇ
TYVYTⓇ
TYVYTⓇ
2021
NAILIKE
PemazyreⓇ
SULINNOⓇ
HALPRYZA®
BYVASDAⓇ
TYVYTⓇ
iti
•
2021 established a fully fledged
team of ~3000 professionals
A growing scale of commercial team and refine management
to broaden coverage and deepen penetration.
Reasonable price solutions and innovative strategies to
reduce financial burden and increase patient's affordability
and accessibility.
We are confident to maintain sustainable and fast revenue growth with delicately-schemed strategies, proven
commercial platform and valuable assets across core therapeutic areas
Innovent
Confidential
Copyright©2022 Innovent
COView entire presentation